CLDINYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CLDWW
Calidi Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.78−0.05 (-6.40%)
Close on Oct 19, 2026
- Market cap
- $1.11M
- P/E (TTM)
- –
- Dividend yield
- –
Calidi Biotherapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Calidi Biotherapeutics | Industry median |
|---|---|---|
| Market Cap | $2.02M | $197.05M |
| Enterprise Value | -$2.00M | $106.56M |
| PB Ratio | 0.65 | 2.14 |
| P/TBV Ratio | 0.65 | 2.46 |
Income (trailing twelve months)
| Measure | Calidi Biotherapeutics | Industry median |
|---|---|---|
| Operating Income | -$17.85M | -$21.44M |
| Pretax Income | -$17.49M | -$14.45M |
| Net Income | -$17.47M | -$22.46M |
| EBITDA | -$16.14M | -$16.91M |
Returns
| Measure | Calidi Biotherapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -713.6% | -53.1% |
| Return on Assets (ROA) | -211.1% | -41.0% |
| Return on Capital Employed (ROCE) | -450.0% | -37.8% |
Balance sheet
| Measure | Calidi Biotherapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $4.07M | $62.42M |
| Total Debt | $45.00K | $120.13M |
| Net Cash (Debt) | $4.03M | $15.68M |
| Net Cash Per Share | $1.56 | $0.65 |
| Equity (Book Value) | $3.13M | $48.79M |
| Book Value Per Share | $1.21 | $1.36 |
| Tangible Book Value | $3.13M | $23.06M |
| Working Capital | $2.19M | $75.77M |
Financial position
| Measure | Calidi Biotherapeutics | Industry median |
|---|---|---|
| Current Ratio | 1.68 | 3.30 |
| Quick Ratio | 1.26 | 2.39 |
| Debt / Equity | 0.01 | 0.51 |
| Interest Coverage | -247.93 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Calidi Biotherapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$17.75M | -$12.35M |
Dividends and yields
| Measure | Calidi Biotherapeutics | Industry median |
|---|---|---|
| Earnings Yield | -863.1% | -21.2% |
Shares
| Measure | Calidi Biotherapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 2,584,180 | 59,128,900 |
| Shares Change (YoY) | 381.2% | 11.1% |
| Shares Change (QoQ) | -82.3% | 0.54% |
| Float | 1,075,110 | 48,744,500 |
| Shares Held by Insiders | 58.4% | 11.8% |
Taxes
| Measure | Calidi Biotherapeutics | Industry median |
|---|---|---|
| Income Tax | $17.00K | $91.50K |
Scores
| Measure | Calidi Biotherapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -36.64 | 0.10 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Calidi Biotherapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.